Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso

J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058.

Abstract

We assessed anti-Vi IgG/IgA responses to typhoid conjugate vaccine (TCV) in children enrolled in a double-blind randomized controlled, phase 2 trial in Burkina Faso. Anti-Vi IgG seroconversion and anti-Vi IgA titers were higher in TCV than control recipients at 30-35 months post-vaccination. TCV induces durable immunity in Burkinabe children vaccinated at 15 months.

Keywords: Africa; Burkina Faso; IgA and IgG; immunogenicity; typhoid conjugate vaccine.

Publication types

  • Randomized Controlled Trial
  • Clinical Trial, Phase II

MeSH terms

  • Antibodies, Bacterial
  • Antibody Formation
  • Burkina Faso
  • Child
  • Humans
  • Immunoglobulin A
  • Immunoglobulin G
  • Infant
  • Typhoid Fever* / prevention & control
  • Typhoid-Paratyphoid Vaccines*
  • Vaccines, Conjugate

Substances

  • Vaccines, Conjugate
  • Typhoid-Paratyphoid Vaccines
  • Immunoglobulin A
  • Immunoglobulin G
  • Antibodies, Bacterial